 Home > Active Ingredient News > Drugs Articles > Haisco introduces Lorecivivint, a new osteoarthritis drug for US$140 million

Haisco introduces Lorecivivint, a new osteoarthritis drug for US$140 million

 Last Update: 2021-09-19
 Source: Internet
 Author: User

Tags

common bone diseases

single phase

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 13, Haisco announced the signing of a cooperation agreement with Biosplice Therapeutics of the United States for the treatment of osteoarthritis, the first innovative drug Lorecivivint, and obtained Lorecivivint's exclusive development, registration and commercialization rights in China
.

To this end, Haisco will pay Biosplice US$20 million in down payment and registration mileage, as well as a certain amount of commercial mileage and royalties based on future sales, with a total transaction amount of US$140 million

Lorecivivint is a drug that is being developed by Biosplice to improve osteoarthritis, and it may become the first innovative drug approved for the improvement of bone and joint function in recent years
.

It is a CLK/DYRK kinase inhibitor that regulates the Wnt pathway and is currently undergoing phase III clinical trials for the treatment of knee osteoarthritis in the United States

According to related research reports, an estimated 303 million people worldwide were affected by osteoarthritis in 2017, of which the knee is the most common site of osteoarthritis
.

It is estimated that 14 million people in the United States suffer from symptomatic knee osteoarthritis (KOA).

Biosplice Therapeutics is an American biotechnology company focusing on innovative drugs at the clinical stage, dedicated to providing treatments based on selective precursor mRNA splicing for major diseases
.

The company is currently developing the first small molecule therapy based on selective precursor mRNA cleavage, and Lorecivivint for the treatment of osteoarthritis is in clinical phase III

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Best Price Isopropylbenzylamine Crystal CAS 102-97-6 N-Isopropylbenzylamine Fast Delivery 99% crystal chemicals

CAS No.: 102-97-6

Pharmacy Grade

$2-2.2/MT EXW

Pregabalin Crystal CAS 148553-50-8 Lyrica Powder 99.0% White Powder Mobelbiochem

CAS No.: 148553-50-8

Pharmacy Grade

$35.00/KG FOB

PTD-DBM 99% freeze dried powder cas1199495-15-2

CAS No.: 1199495-15-2

Pharmacy Grade

$3-3.2/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.